Table 3.
Grade 3 and 4 non-hematologic adverse events summarized from the included five trials.
| Grade 3/4 adverse events | Study | Docetaxel | Paclitaxel | ||
|---|---|---|---|---|---|
| Incidence (%) | Regimen | Incidence (%) | Regimen | ||
| Peripheral Edema | Jones et al. | 6.8 | 100 mg/m2 Q3W | 0.5 | 175 mg/m2 Q3W |
| Cassier et al. | 2.8 | 75 mg/m2 Q3W | 0.0 | 175 mg/m2 Q3W | |
| Kelly et al. | 0.0 | 75 mg/m2 Q3W | 0.3 | 80 mg/m2 QW | |
| Watanabe et al. | 12.6 | 75 mg/m2 Q3W | 0.0 | 175 mg/m2 Q3W | |
| Peripheral Neuropathy | Cassier et al. | 0.0 | 75 mg/m2 Q3W | 7.8 | 175 mg/m2 Q3W |
| Kelly et al. | 4.8 | 75 mg/m2 Q3W | 2.4 | 80 mg/m2 QW | |
| Neurosensory | Jones et al. | 7.2 | 100 mg/m2 Q3W | 4.1 | 175 mg/m2 Q3W |
| Swain et al. | 1.0 | 75 mg/m2 Q3W | 6.7 | 175 mg/m2 Q2W | |
| Watanabe et al. | 3.8 | 75 mg/m2 Q3W | 5.7 | 175 mg/m2 Q3W | |
| Neuromotor | Jones et al. | 5.0 | 100 mg/m2 Q3W | 2.3 | 175 mg/m2 Q3W |
| Watanabe et al. | 1.3 | 75 mg/m2 Q3W | 0.4 | 175 mg/m2 Q3W | |
| Nausea | Jones et al. | 5.4 | 100 mg/m2 Q3W | 2.7 | 175 mg/m2 Q3W |
| Kelly et al. | 4.1 | 75 mg/m2 Q3W | 1.7 | 80 mg/m2 QW | |
| Swain et al. | 3.9 | 75 mg/m2 Q3W | 3.2 | 175 mg/m2 Q2W | |
| Watanabe et al. | 1.2 | 75 mg/m2 Q3W | 0.4 | 175 mg/m2 Q3W | |
| Vomiting | Jones et al. | 3.2 | 100 mg/m2 Q3W | 0.0 | 175 mg/m2 Q3W |
| Kelly et al. | 1.7 | 75 mg/m2 Q3W | 0.0 | 80 mg/m2 QW | |
| Swain et al. | 2.8 | 75 mg/m2 Q3W | 2.9 | 175 mg/m2 Q2W | |
| Watanabe et al. | 0.8 | 75 mg/m2 Q3W | 0.0 | 175 mg/m2 Q3W | |
| Diarrhea | Jones et al. | 5.4 | 100 mg/m2 Q3W | 0.5 | 175 mg/m2 Q3W |
| Kelly et al. | 5.8 | 75 mg/m2 Q3W | 4.0 | 80 mg/m2 QW | |
| Swain et al. | 6.8 | 75 mg/m2 Q3W | 2.2 | 175 mg/m2 Q2W | |
| Watanabe et al. | 1.9 | 75 mg/m2 Q3W | 0.4 | 175 mg/m2 Q3W | |
| Constipation | Kelly et al. | 2.0 | 75 mg/m2 Q3W | 0.7 | 80 mg/m2 QW |
| Watanabe et al. | 0.4 | 75 mg/m2 Q3W | 0.4 | 175 mg/m2 Q3W | |
| Skin Disorders | Jones et al. | 4.5 | 100 mg/m2 Q3W | 0.0 | 175 mg/m2 Q3W |
| Kelly et al. | 0.3 | 75 mg/m2 Q3W | 1.0 | 80 mg/m2 QW | |
| Mucositis (including stomatitis) | Jones et al. | 10.8 | 100 mg/m2 Q3W | 0.0 | 175 mg/m2 Q3W |
| Cassier et al. | 0.0 | 75 mg/m2 Q3W | 1.3 | 175 mg/m2 Q3W | |
| Swain et al. | 0.9 | 75 mg/m2 Q3W | 0.8 | 175 mg/m2 Q2W | |
| Kelly et al. | 1.7 | 75 mg/m2 Q3W | 0.0 | 80 mg/m2 QW | |
| Elevated AST or ALT | Watanabe et al. | 0.4 | 75 mg/m2 Q3W | 3.1 | 175 mg/m2 Q3W |
| Elevated Bilirubin | Watanabe et al. | 0.0 | 75 mg/m2 Q3W | 0.4 | 175 mg/m2 Q3W |
| Fatigue | Kelly et al. | 22.5 | 75 mg/m2 Q3W | 8.4 | 80 mg/m2 QW |
| Swain et al. | 9.2 | 75 mg/m2 Q3W | 9.1 | 175 mg/m2 Q2W | |
| Watanabe et al. | 1.9 | 75 mg/m2 Q3W | 1.9 | 175 mg/m2 Q3W | |
| Asthenia | Jones et al. | 20.7 | 100 mg/m2 Q3W | 5.0 | 175 mg/m2 Q3W |
| Cassier et al. | 5.6 | 75 mg/m2 Q3W | 6.5 | 175 mg/m2 Q3W | |
| Arthralgia | Kelly et al. | 1.0 | 75 mg/m2 Q3W | 0.0 | 80 mg/m2 QW |
| Swain et al. | 4.1 | 75 mg/m2 Q3W | 11.8 | 175 mg/m2 Q2W | |
| Watanabe et al. | 1.6 | 75 mg/m2 Q3W | 7.5 | 175 mg/m2 Q3W | |
| Myalgia | Jones et al. | 2.7 | 100 mg/m2 Q3W | 3.2 | 175 mg/m2 Q3W |
| Kelly et al. | 10.9 | 75 mg/m2 Q3W | 6.4 | 80 mg/m2 QW | |
| Watanabe et al. | 0.8 | 75 mg/m2 Q3W | 5.3 | 175 mg/m2 Q3W | |
Jones et al. did not report incidence of 3% or lesser in either treatment group.
Data of adverse events from Cassier et al. were from Cycle 5-8 in the study, when the patients were combined with doxorubicin.